Nuvalent (NUVL) Other financing activities (2021 - 2023)
Nuvalent's (NUVL) quarterly Other financing activities came in at $13.6 million in Q4 2023, up 1003.0% YoY from $1.2 million in Q4 2022, and up 3292.49% on a QoQ basis from -$426000.0 in Q2 2023.
Nuvalent (NUVL) Other financing activities (2021 - 2023) Analysis & Trends
Nuvalent (NUVL) has 3 years of Other financing activities data on file, last reported at $13.6 million in Q4 2023.
- Quarterly Other financing activities rose 1003.0% year-over-year to $13.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $13.8 million (up 649.62% YoY) and the FY2023 annual result came in at $13.8 million, up 649.62% from the prior year.
- Other financing activities rose to $13.6 million in Q4 2023, from -$426000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $177.3 million in Q3 2021 to a low of -$177.3 million in Q4 2021.
- A 3-year average of $1.7 million and a median of $394000.0 in 2022 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 4661.54% in 2023, down 313.0% in 2023.
- Tracing NUVL's Other financing activities over 3 years: stood at -$177.3 million in 2021, then surged by 100.7% to $1.2 million in 2022, then jumped by 1003.0% to $13.6 million in 2023.
- The last three Other financing activities figures came in at $13.6 million (Q4 2023), -$426000.0 (Q2 2023), and $619000.0 (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 13.60 Mn |
| Dec 31, 2023 | 13.60 Mn |
| Jun 30, 2023 | -426,000.00 |
| Jun 30, 2023 | -426,000.00 |
| Mar 31, 2023 | 619,000.00 |
| Mar 31, 2023 | 619,000.00 |
| Dec 31, 2022 | 1.23 Mn |
| Dec 31, 2022 | 1.23 Mn |
| Sep 30, 2022 | 394,000.00 |
| Sep 30, 2022 | 394,000.00 |
| Jun 30, 2022 | 200,000.00 |
| Jun 30, 2022 | 200,000.00 |
| Mar 31, 2022 | 13,000.00 |
| Mar 31, 2022 | 13,000.00 |
| Dec 31, 2021 | -177.26 Mn |
| Dec 31, 2021 | -177.26 Mn |
| Sep 30, 2021 | 177.27 Mn |
| Sep 30, 2021 | 177.27 Mn |